Literature DB >> 18234203

Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia.

Christian Breymann1, Flaviu Gliga, Christina Bejenariu, Nina Strizhova.   

Abstract

OBJECTIVES: To compare the safety and efficacy of iron carboxymaltose with ferrous sulfate to treat iron deficiency anemia in the post partum.
METHODS: Patients were randomized (2:1 ratio) to receive iron carboxymaltose (up to 3 weekly doses of 1000 mg maximum, applied in 15 min; n=227) or ferrous sulfate (100 mg twice daily, 12 weeks; n=117). Changes in hemoglobin and iron stores up to week 12 were analyzed.
RESULTS: Iron carboxymaltose was as effective as oral iron sulfate in changing hemoglobin, despite the much shorter treatment period (2 weeks vs 12 weeks). Ferritin levels were significantly higher. Except for injection site burning, iron carboxymaltose was better tolerated than ferrous sulfate, mainly concerning gastrointestinal side effects. There were no safety concerns identified in breast-fed infants.
CONCLUSION: Parenteral iron carboxymaltose is a safe and effective treatment option for postpartum anemia, with advantages of a shorter treatment period, better compliance, rapid normalization of iron storages, and lower incidence of gastrointestinal side effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18234203     DOI: 10.1016/j.ijgo.2007.10.009

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  41 in total

Review 1.  Diagnosis and management of iron deficiency anemia in patients with IBD.

Authors:  Jürgen Stein; Franz Hartmann; Axel U Dignass
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10-05       Impact factor: 46.802

2.  Oral vs intravenous iron therapy for postpartum anemia: a systematic review and meta-analysis.

Authors:  Pervez Sultan; Sohail Bampoe; Raj Shah; Nan Guo; Jaclyn Estes; Christopher Stave; Lawrence Tim Goodnough; Stephen Halpern; Alex James Butwick
Journal:  Am J Obstet Gynecol       Date:  2018-12-19       Impact factor: 8.661

3.  Ferric carboxymaltose.

Authors:  Dennis J Cada; Terri L Levien; Danial E Baker
Journal:  Hosp Pharm       Date:  2014-01

4.  Comparative efficacy and safety of intravenous ferric carboxymaltose (Ferinject) and iron(III) hydroxide dextran (Cosmofer) in pregnancy.

Authors:  B Myers; O Myers; J Moore
Journal:  Obstet Med       Date:  2012-04-23

Review 5.  Ferric Carboxymaltose: A Review in Iron Deficiency.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

Review 6.  Ferric carboxymaltose: a review of its use in iron deficiency.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2015-01       Impact factor: 9.546

7.  IV Ferric Carboxymaltose Vs Oral Iron in the Treatment of Post-partum Iron Deficiency Anaemia.

Authors:  Sree Chandana Damineni; Suchitra Thunga
Journal:  J Clin Diagn Res       Date:  2016-11-01

Review 8.  Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.

Authors:  Katherine A Lyseng-Williamson; Gillian M Keating
Journal:  Drugs       Date:  2009       Impact factor: 9.546

9.  Treatment of Iron Deficiency with or without Anaemia with Intravenous Ferric Carboxymaltose in Gynaecological Practices - A Non-Interventional Study.

Authors:  R Herfs; L Fleitmann; I Kocsis
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-01       Impact factor: 2.915

Review 10.  Modern iron replacement therapy: clinical and pathophysiological insights.

Authors:  Domenico Girelli; Sara Ugolini; Fabiana Busti; Giacomo Marchi; Annalisa Castagna
Journal:  Int J Hematol       Date:  2017-12-01       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.